Lixte Biotechnology Holdings Inc (LIXT) Quote

LIXT............................................https://stockcharts.com/h-sc/ui?s=lixt&p=W&b=5&g=0&id=p86431144783






.................thx..........................

$1.06 + 54% ...Company no longer intends to pursue a public offering under the Registration Statement at this time PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange  no longer intends to pursue a public offering under the Registration Statement at this time ommission (the “SEC”) of the Company’s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as th

Early withdrawal has its benefits 
$3.29+ 44%

LIXT..................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783

LIXT 1.89 + 44%

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

LIXT under $3

LIXT under $5

Another one hit wonder it moved on news

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Perfectly predictable chart,pullbacks to sma 100% so far

No debt,current ratio $7.49

Some $60k-$90k buys,institutional buys starting?12%currently,up2%

-.02 accumulation Friday,now +.115,loading going on!!

Not optionable,shares to short dropping

1.73M float/s.o. 2.25M,12Xs buying vol

LIXT new 52 week low

July 17, 2023
8:30 am ET
Preclinical Results of LIXTE Biotechnology's Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Globe Newswire

Amazing to watch 1.64 to flat same day. SEC sleeps again

LIXT......................................https://stockcharts.com/h-sc/ui?s=LIXT&p=W&b=5&g=0&id=p86431144783

LIXT NEWS 1.50'S


MAYBE OFFERING NEXT


WE KNOW THEY NEED IT= $$$$$$$$$$$$$$$$$$$$

LIXT: Just more "HYPER-STIMULATION" of the PRICE of their stock!! (HA-HA!!!)

1.01 WAS LOD SUCH A SHAME

Still no offering… we bouncing here??

LIXT 1.34X1.36 could go again, if volume comes in and squeezes= $LIXT here is the technical chart with the inside bar on daily..... i buy the dip never the rip +100 or 200% works better pic.twitter.com/k6IlsHMUIy— Antonio Costa (@ACInvestorBlog) February 8, 2023

1.29 I think they want people to chase a pop before the company wakes up and announces an offer


thats what I think

LIXT trying 1.30 break after just dumped to 1.16 again


all these are PD's controlled by robots

LIXT: And gettin' even LOWER in the A.F. routine, Boss.

PS: But SOUN, BBAI, et al., all UP a bit behind that Bing Search Engine news & 'AI Voice' stuff.

yup 1.39

LIXT: Indeed, G-2-G!! Evidently, Peeps are getting --- as they should be --- rather JADED behind the obligatory, NEXT-GREAT-CANCER-CURE-OF-THE-DAY, routines!! And the subject one here, is nowhere near the HUMAN Phase studies level. And, their PR was FUNNY, to boot!!! E.g., stimulate, feed, promote, & otherwise AUGMENT the Cancer cells entire cellular STRUCTURES to such extreme extent, that they FORGET that they are indeed CANCER cells in the FIRST PLACE --- and then they will act NORMAL, & NOT want to metastasize anywhere!!!!! Where they KIDDING us all??????

LIXT 2.56 @ 3:30 NOW 1.50

PRETTY SICK...NO???

ITS NOT LIKE THERE WAS AN OFFERING FOR CHEAP SAKES

LIXT:
https://www.marketscreener.com/quote/stock/LIXTE-BIOTECHNOLOGY-HOLDI-302255/news/LIXTE-BIOTECHNOLOGY-HOLDINGS-INC-REPORTS-THAT-ITS-LEAD-CLINICAL-COMPOUND-LB-100-CAN-KILL-CANCER-42921763/

Thx for the heads up… got me 3k just below 2$ but stop is in

HUGE NEWS

https://finviz.com/quote.ashx?t=LIXT&ty=c&ta=1&p=d

I belive this will see a nice move near therm

Took a position $1.30

$LIXT

Loaded 1,18

Corrupted MM or short hedge fund criminals are engaged in all out corrupt manipulation in the after hours to steal shares, or use their tools of manipulation to cover shorts,this kind of criminal act by this trash needs to get burned.

Good Morning.

I lost money on the last run. I got caught in a massive dump (like today).
I watched this a bit today, and it's the same trading pattern.
Looks like it's a combination of the company dumping shares, and heavy shorting.

Yep in . Thanks!

Being the savvy trader I am, I was waiting.......

to see if the $2.40 support level held.

I'm still waiting.......BWAHAHAHAHA

Congrats longs!

Now every company want to release similar news?? Imo

low ss https://finviz.com/quote.ashx?t=LIXT&ty=c&ta=1&p=d

Thank you Buddy !

Very nice

https://ih.advfn.com/stock-market/NASDAQ/lixte-biotechnology-LIXT/stock-news/87813772/lixte-biotechnology-announces-preclinical-results

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Source: GlobeNewswire Inc.

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers, and Stichting Oncode Institute (Oncode Institute), Utrecht, a major independent cancer research center, has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergistic anti-cancer effects in cancer patients.
Lixte previously announced its entry into a collaboration with the NKI and Oncode Institute to identify the most promising drugs to be used in combination with Lixte’s LB-100 or with one of Lixte’s LB-100 analogues to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.

John S. Kovach, MD, the founder and CEO of Lixte, commented "The new findings support the hypothesis advanced by Professor Bernards at the NKI (Dias and Bernards, Mol Onc, 2021) that rather than the usual therapeutic approach to cancer – inhibiting overactive pathways that drive cancer growth – further stimulation of those pathways can overwhelm the cancer cells, rendering them exceptionally vulnerable to particular stress-targeted drugs, while sparing the normal cells. This ‘paradoxical intervention’ is truly groundbreaking and may be applicable to a broad range of cancers."

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, by demonstrating that this compound is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells damaged by chemotherapy or other cancer therapies to continue to replicate before repairing the damage, leading to more efficient killing of cancer cells. LB-100 is being tested in three clinical cancer treatment studies, with others in planning. www.lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533



LIXT $$$$

Not much Shares traded until now , but it‘s going up and up

LIXT $$$$